m. tuberculosis

Pyrazinamide (Pyrazinecarboxamide), an antimycobacterial, is utilized therapeutically as an antitubercular agent, which is a synthetic pyrazinoic acid amide derivative.

DuP-721 is a broad-spectrum, orally active antibacterial agent that inhibits a variety of clinically susceptible and resistant bacteria, particularly [M. tuberculosis].

C-215 is a novel inhibitor of mycobacterial membrane protein large 3 (MmpL3).

Norverapamil hydrochloride (D591 hydrochloride) ((±)-Norverapamil hydrochloride) is an N-demethylated metabolite of Verapamil and it is an L-type calcium channel blocker and a P-glycoprotein (P-gp) function inhibitor.

Acid phosphatase, M. tuberculosis (EC 3.1.3.2), is one of the key enzymes involved in the metabolism of Mycobacterium tuberculosis and serves as a potential target for anti-tuberculosis compounds.

GSK2556286 (GSK286) is an orally active inhibitor of Mycobacterium tuberculosis (M. tuberculosis), effective against multidrug-resistant (MDR), extensively drug-resistant (XDR), and drug-sensitive (DS) strains. It inhibits the growth of human macrophages with an IC50 value of 0.07 μM.

AU1235 is a Mycobacterium tuberculosis inhibitor.

Cefsulodin sodium (Sulcephalosporin) hydrate is a β lactam antibiotic.

Methyl quinoline-2-carboxylate (Methyl 2-quinolinecarboxylate) inhibits the binding of Mycobacterium tuberculosis.

Thiacetazone (Diazam) is a thiosemicarbazone that thioacetazone treatment of pulmonary tuberculosis

Antimycobacterial agent-4 (4-nitro-N-[4-(2-pyridyl)thiazol-2-yl]benzamide) has antibacterial activity against Mycobacterium tuberculosis.

Mycobacterium Tuberculosis-IN-7 (Compound 4c) inhibits M. tuberculosis H37Ra with an MIC of 5.34 μg/mL and exhibits mild cytotoxicity against cancer cells Vero, A549, and HepG2 (IC50 > 50 μM).

Mitonafide (NSC-300288) suppresses the activity of M. tuberculosis NAD+ dependent DNA ligase A. Mitonafide is a DNA intercalating agent.

ML338 is a selective small molecule inhibitor probe specifically targeting non-replicating Mycobacterium tuberculosis bacilli. It exhibits potent activity against non-replicating M. tuberculosis, with IC90 and IC99 values of 1 μM and 4 μM, respectively, as determined by CFU. This compound, ML338, is an invaluable tool for identifying essential functions and vulnerabilities of M. tuberculosis bacilli under nutrient deprivation conditions. Additionally, ML338 is highly useful for studying M. tuberculosis chemotherapy.

Q203 (Telacebec) is a novel potent anti-tuberculosis agent targeting cytochrome b subunit qcrB and inhibits M. tuberculosis H37Rv (MIC50: 2.7 nM).

Lansoprazole Sulfide-D4 is a deuterium labeled Lansoprazole Sulfide. Lansoprazole Sulfide (T21128) is an orally active anti-TB (Mycobacterium tuberculosis) agent with IC50 values of 0.59 μM intracellularly and 0.46 μM in broth.Lansoprazole Sulfide is an active metabolite of the proton pump inhibitor Lansoprazole.

NITD-349 is an inhibitor of MmpL3. It shows highly potent anti-mycobacterial activity with MIC50 of 23 nM against virulent Mycobacterium tuberculosis H37Rv.

Mycobacterium Tuberculosis-IN-6 (compound b1) is an inhibitor of the enoyl reductase InhA from Mycobacterium tuberculosis, with an IC50 value of 7.74 μM. It is useful in antibacterial research.

Mycobacterium Tuberculosis-IN-8 (Compound 6g) is a selective inhibitor of Mycobacterium tuberculosis (MTB), with a MIC value of 6.25 µg/mL against MTB H37Rv. It demonstrates potent antitubercular activity by inhibiting mycolic acid biosynthesis, which is crucial for maintaining bacterial cell wall integrity. Mycobacterium Tuberculosis-IN-8 holds potential for research in antitubercular agents.

GSK1733953A can be used as a small molecule Mycobacterium tuberculosis respiration inhibitor with an inhibitory effect on MenG activity and an IC50 value of 2.6 ± 0.6 μM.GSK1733953A is a selective biphenylbenzamide with an inhibitory effect on the catalytic methylation of the Mycobacterium tuberculosis desmethylnaphthoquinone methyltransferase, and the MIC of GSK1733953A against Mycobacterium tuberculosis H4Rv was 8.37 μg/ml. MIC of 8.37 μg/ml and MIC of 1.2 to 9.6 μg/ml against drug-resistant strains.GSK1733953A is a candidate compound for the treatment of tuberculosis.

S.pombe lumazine synthase-IN-1 is a compound that inhibits lumazine synthases, with Ki values of 243 μM for Schizosaccharomyces pombe and 9.6 μM for Mycobacterium tuberculosis, respectively[1].

Thiophene-2 (TP2) is a targeted inhibitor of polyketide synthase 13 (Pks13), specifically designed to disrupt mycolic acid biosynthesis, effectively inducing rapid cell death in mycobacteria. It demonstrates notable anti-tuberculosis activity and exhibits a minimum inhibitory concentration (MIC) value of 1 μM against Mycobacterium tuberculosis.

1. (+)-(3R,8S)-Falcarindiol is a potential new anticancer agent that exerts its activity through inducing ER stress and apoptosis. 2. Falcarindiol induces immunosuppressive effects in vitro and in vivo and might be a novel therapy for autoimmune or allergic diseases. 3. Falcarindiol has protective effect against CCl(4) toxicity , in part, be explained by anti-lipid peroxidation activity associated with the induction of the GSTs including GSTA4.

Transketolase-IN-4 is a transketolase inhibitor with an IC50 value of 3.9 μM.Transketolase-IN-4 inhibited Mycobacterium tuberculosis DXS with an IC50 value of 114.1 μM. Transketolase-IN-4 inhibited the SW620, LS174T, and MIA PaCa-2 tumor cell proliferation.